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Research Shorter GT repeat polymorphism in the heme 
oxygenase-1 gene promoter has protective effect 
on ischemic stroke in dyslipidemia patients
Chyi-Huey Bai1,2, Jiunn-Rong Chen3, Hou-Chang Chiu4, Chia-Chi Chou5, Lee-Young Chau*†6 and Wen-Harn Pan*†6
Abstract
Background: The microsatellite polymorphism of heme oxygenase (HO)-1 gene promoter has been shown to be 
associated with the susceptibility to ischemic event, including coronary artery disease (CAD), myocardial infarction, and 
peripheral vascular disease. We aimed to examine whether the length of (GT)n repeats in HO-1 gene promoter is 
associated with ischemic stroke in people with CAD risk factors, especially low level of HDL.
Methods: A total of 183 consecutive firstever ischemic stroke inpatients and 164 non-stroke patients were screened for 
the length of (GT)n repeats in HO-1 promoter. The long (L) and short (S) genotype are defined as the averaged repeat 
number >26 and 26, respectively.
Results: Stroke patients tended to have more proportions of hypertension, diabetics and genotype L, than those of 
genotype S. Patients with genotype L of HO-1 gene promoter have higher stroke risk in comparison with genotype S 
especially in dyslipidemia individuals. The significant differences on stroke risk in multivariate odds ratios were found 
especially in people with low HDL-C levels.
Conclusions: Subjects carrying longer (GT)n repeats in HO-1 gene promoter may have greater susceptibility to 
develop cerebral ischemic only in the presence of low HDL-C, suggesting the protective effects in HO-1 genotype S in 
the process of ischemic stroke, particularly in subjects with poor HDL-C status.
Background
Heme oxygenese (HO) is a rate-limiting enzyme in heme
degradation, leading to the liberation of free iron, carbon
monoxide (CO) and biliverdin[1]. HO-1, one of HO iso-
forms. is a stress-responsive protein induced by various
oxidative agents[1,2]. Over past few years, numerous stud-
ies have revealed the important function of HO-1 in cardiol-
ogy by aspects such as inflammation, antioxidant function,
apoptosis, hypoxia and ischemia/reperfusion injury, and
angiogenesis [3].
HO-1 as a cytoprotective defense mechanism against oxi-
dative insults is through the antioxidant activities of biliver-
din and its metabolite, bilirubin [4], as well as the anti-
imflammatory, antifibrinolytic and vasodilative actions of
CO [2,5,6]. HO-1 also is up-regulated during cerebral isch-
emia [7-10], in relation to the severity of brain injury [11]
or aneurysms [7], and also exert a protective effect on neu-
ronal cell against oxidative stress [12,13]. The first case of
HO-1 deficiency in human was identified in 1999 [14], the
patient suffered persistent hemolytic anemia and abnormal
coagulation/fibrinolysis system associated with elevated
thrombomodulin and von Willebrand factor, indicating per-
sistent vascular injury. Two studies focused HO-1 mocro-
glia/macrophage and cerebrovascular disease speculated
the prolong expression of HO-1 in traumatic brain injury,
cerebral infarction and aneurysms [7,10]. HO-1 is also
induced in atherosclerotic lesions of human and experimen-
tal animals, and has a protective role in the blood vessel
wall during atherogenesis [15,16]. Overexpression of HO-1
in arterial walls reduces lesion formation as well as intimal
hyperplasia subsequent to vascular injury, supporting its
vasoprotective function [17-19]. Several positive physio-
logical effects exerted by HO-1 as anti-inflammatory and
cytoproective functions in cardiovascular and peripheral
vascular disease [20].
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The human HO-1 gene is mapped on chromosome 22q12
with a (GT)n dinucleotide repeat polymorphism in the prox-
imal promoter region [21,22]. It has been shown that the
(GT)n repeat is highly polymorphic and modulates the tran-
scriptional activity of HO-1 gene [23,24]. Promoter con-
taining longer (GT)n  repeats has lower transcriptional
activity in vascular cells [24]. We and others have reported
that human subjects carrying longer (GT)n repeats have
increased susceptibility to the development of coronary
artery disease [4,24,25], post-angioplasty restenosis [26-28]
and advanced peripheral artery disease [29], indicating that
HO-1 promoter polymorphism is likely to act as an candi-
date in the genetic determinant involved in vascular dis-
ease.
Ischemic stroke is a common disease with high mortality
rate in populations [30], earlier studies have revealed the
family history as an independent risk factor, suggesting the
involvement of genetic components in the pathogenesis of
ischemic stroke [31]. Ischemic stroke shares many common
risk factors with other vascular disease, such as hyperten-
sion, diabetes, hyperlipidemia and smoking. Although the
neuroprotective effect and the ability of reduced infarct size
of HO-1 have been shown [32], the only study focused on
recurrent and first ischemic cerebrovascular events still not
reported a significant association between HO-1 promoter
polymorphism and stroke [3]. In view of the vital role of
HO-1 in vascular protection, here we aimed, especially in
those stroke patients with no history of cerebro- or cardio-
vascular events, to examine the association between the risk
of ischemic stroke and the length of the (GT)n repeats of the
HO-1 gene promoter under several vascular conditions:
hypertension, diabetes, lipids abnormality and smoking. We
also aimed to explore the interaction of the HO-1 genotype
and above risk factors on ischemic stroke.
Methods
Participants
A total of 183 consecutively hospitalized first-ever isch-
emic stroke (IS) inpatients and 164 non-stroke (NS) outpa-
tients were recruited from neurological ward and clinics of
Shin Kong WHS Memorial Hospital in Taipei city from
mar 1996 to Dec 1999. These first-ever inpatients were
recruited within the first 48 h (20.3 ± 14.9 h) of the stroke
onset. Inclusion criteria for IS patients were: (a) IS patients
admitted within 48 hours of onset; (b) age greater than 40
years; (c) no prior history of stroke and myocardial infarc-
tion. NS outpatients are those with complaints of nonspe-
cific symptoms such as peripheral vestibulopathy,
radiculopathy, low back pain, insomnia, Parkinson's dis-
ease, myalgia, arthralgia, muscle pain, muscle stiffness, or
headache. Neurologist had confirmed that these NS patients
had no evidence of stroke and myocardial infarction. The
controls were enrolled during the same recruitment periods
with cases, and the recruitment was performed blindly with
respect to patient's clinical data and HO-1 genotypes. The
study was approved by Ethics Committee/Institutional
Review Board (EC/IRB) of the hospital, and informed con-
sent was obtained from every subject.
Data Collection and measurement
Information on age, sex, residential area, and risk factors of
stroke was obtained via interview within 3 to 7 days of
admission. Diagnosis of stroke and stroke subtype of each
subject was confirmed by a single neurologist (the second
author) based on data from clinical assessment and neuro-
logical images such as computerized tomography (CT), and
other studied tests. Cerebral infarction was defined as a
focal neurological deficit of sudden onset that persisted
beyond 24 hours in surviving patients with indication of the
presence of infarction and the absence of hemorrhage,
which was documented by brain CT or by MRI. Informa-
tion on medication and on chronic diseases such as hyper-
tension, diabetes mellitus, coronary heart disease, left
ventricular hypertrophy (LVH), atrial fibrillation (AF), and
other related diseases were transcribed from various types
of medical records including medical charts, lab reports,
nursing diaries and reports of ECG, chest X-ray, and
echocardiogram.
Blood samples of the patients were drawn after at least an
8-hour over-night fast. Fasting venous blood was drawn
into two 5cc heparinized tubes. Plasma and buffy coat were
prepared immediately after drawing and stored at -70°C.
Heparinized plasma was used to measure total cholesterol
(TC) and high-density lipoprotein cholesterol (HDL-C)
(Lieberman-Burchard method), triglyceride (Bucolo
method), and glucose (Keston method), with a Hitachi
autoanalyzer (Hitachi 7250, Hitachi, Japan). Low-density
lipoprotein cholesterol (LDL-C) value was calculated from
levels of TC, triglyceride and HDL-C[33]. The coefficient
of variation of 65 duplicated samples was 2.2% for TC,
3.1% for triglyceride, 2.8% for HDL-C and 2.5% for glu-
cose. The stroke patients were followed from admission to
3 months later. In this study, we analyzed the data of the
blood after 3 months of onset in stroke patients to ensure
that blood levels were stabilized.
Hypertension was defined by systolic/diastolic blood
pressure 140/90 mm Hg or by receiving antihypertensive
therapy. The measurement of blood pressure from left arm
was obtained and used. Diabetes was defined by fasting
plasma glucose 126 mg/dL or by taking hypoglycemic
medication. Patients with hypercholesterolemia, hypertrig-
lyceridemia, high LDL-C level and low HDL-C level were
defined by total cholesterol level 240 mg/dL, triglyceride
level  200 mg/dL, TC/HDL-C ratio 5, LDL-C level
130 mg/dL, HDL-C level < 40 mg/dL (for men)/< 50 mg/
dL (for women), respectively. Obesity was defined as bodyBai et al. Journal of Biomedical Science 2010, 17:12
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mass index 27. Ever-smoker was those subjects with cur-
rent or past smoking habits.
An extracranial carotid duplex ultrasound machine
(SONO 1000; Hewlett-Packard Company; USA), with a
transducer frequency of 7.5 Hz and color frequency of 5.4
Hz, was used. A standardized protocol was established. The
near and far walls of the left and right proximal common
carotid artery (CCA), distal CCA, proximal external carotid
artery, proximal internal carotid artery, and carotid bifurca-
tion were examined by B-mode duplex scanning. The
degree of plaque was graded as follows: 0 = no plaque; 1 =
one small plaque < 30% of the vessel diameter; 2 = one
medium plaque between 30% and 50% of the vessel diame-
ter or multiple small plaques; 3 = one large plaque > 50% of
the vessel diameter or multiple plaques with at least one
medium plaque. The grades in each segment of all carotid
arteries were added to create a summary plaque score corre-
sponding to the extent of carotid atherosclerosis.
Analysis of Length Variability of (GT)n Repeats in HO-1 
Gene Promoter
Genomic DNAs were extracted from storaged leukocytes
by conventional procedures. The 5'-flanking region con-
taining (GT)n repeats of the HO-1 gene was amplified by
PCR with a FAM-labeled sense primer, 5'-AGAGCCTG-
CAGCTTCTCAGA-3', and an antisense primer, 5'-
ACAAAGTCTGGCCATAGGAC-3', according to the pub-
lished procedure [34]. The PCR products were mixed
together with GenoType™ TAMRA DNA ladder (size
range 50-500 bp) (GibcoBRL) and analyzed with auto-
mated DNA sequencer (ABI Prism™ 377). Each size of the
(GT)n repeat was calculated using the GeneScan Analysis
software (PE Applied Biosystems).
Statistical analysis
The distribution of the numbers of (GT) n repeats of two
DNA strands were studied, and the frequency of repeats in
patients was plotted. Assuming a co-dominant (additive)
trait model, HO-1 genotypes were defined by the averaged
length of (GT)n repeats. Averaged length of (GT) n repeats
of the HO-1 gene promoter was calculated for each patient.
Age was expressed as mean ± SD and compared by Stu-
dent's t tests. Chi-square test was used to examine whether
CAD risk factors (hypertension, diabetes, all lipids abnor-
malities, and smoking habits) and some other characteris-
tics differed between IS patients and NS controls. Chi-
square test was also used to compare frequency of genotype
S and L between IS patients and NS controls in all subjects
or in subgroups stratified by above risk factors. However,
only the figure on HDL-C was shown. The associations
between stroke status and HO-1 genotypes were examined
by stratifying on stroke and cardiovascular (CVD) risk fac-
tors. The risk of odds ratio (OR) was showed after adjusted
the following factors: age, sex, hypertension, diabetes,
smoking habits, lipid abnormalities, obesity, or plaque score
if necessary. Two sides p value was calculated, and signifi-
cant level was accepted at P < 0.05. Statistical calculations
were performed using SAS software package (version 9.1).
Results
The length of the (GT)n repeats in the human HO-1 gene
promoter region ranged from 15 to 39, as shown in figure 1.
The distribution had two peaks at (GT)23  and (GT)30,
respectively. The averaged length of the (GT)n repeats had
similar distribution, but they ranged from15 to 35 with
peaks at 27 and 30. Therefore, we defined genotype short
(S) for those with averaged length 26 GT repeats, and
genotype long (L) for those with length of >26 GT repeats,
which included around 70 percent of patients.
Stroke patients were significantly older (mean aged 65.5
± 12.2 versus 62.8 ± 11.5 in controls, p = 0.0465). They
also had significantly greater proportion of diabetes, hyper-
tension, LDL-C, lowered HDL-C level, obesity, and higher
plaque score than the controls (Table 1). Additionally,
stroke patients tended to have more males, more ever-
smokers, more lipids abnormalities and more genotype L
than controls. However, no significant differences were
found between IS and NS patients.
Table 2 shows the distribution of genotypes of HO-1 gene
promoter by several cardiovascular risk factors, respec-
tively, in stroke patients and in non-stroke controls. A
higher proportion of genotype L was observed in stroke
patients than in non-stroke patients in those with lowered
HDL-C (p = 0.0056), normal TC level (p = 0.0490), and
normal LDL-C level (p = 0.0270), so was in those with high
TC/HDL-C ratio with borderline significant (p = 0.0747).
Stroke patients tended to have higher frequency of geno-
type L than non-stroke patients in patients with diabetes,
hypertension, hyperlipidemia, ever-smoking habit and high
carotid plaque score, respectively; but these were not statis-
tically significant (Table 2). In addition, stratified analysis
further showed that diabetics tended to have higher propor-
tion of genotype L than non-diabetics. But the significance
was only shown for stroke patients (p = 0.0389).
According the results of table 2, we next examined
whether the genotype of the human HO-1 gene promoter
was associated with ischemic stroke under different lipids
conditions: normal TC level and LDL-C level as well as
abnormal HDL-C level (Table 3). In analysis of these sub-
group, only the significant adjusted ORs were showed in
those with lowered HDL-C levels (Model I and II OR & p
value, 2.07, 0.0303 and 2.02, 0.0405, respectively). The
multivariate ORs were not significant in the analyses of TC
and LDL-C. For describing the interaction of HDL-C and
genotypes, figure 2 shows the age- and sex- adjusted OR on
stroke risk for HO-1 gene genotypes by the HDL-C status.
Patients of genotype L tended to have larger ORs than thoseBai et al. Journal of Biomedical Science 2010, 17:12
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Figure 1 Allele frequency distribution of (GT)n repeats and the averaged (GT)n repeats in the HO-1 gene in 347 patients.
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f genotype S in people carrying lowered HDL-C status
(genotype L vs S in OR: 3.20 vs 1.44 in low HDL-C group),
as well as other CVD risk factors (detailed data not shown).
Similar trend was found but with no statistical significance.
In addition, we also examined the increased effects for gen-
otype L in comparing with S in each high risk factor profile
group. In those with low HDL-C, subjects with genotype L
had significantly greater stroke risk than those with geno-
type S (p = 0.007).
Discussion
Our study revealed that shorter HO-1 promoter genotype
has the protective effect on ischemic stroke, especially in
the patients with lower HDL-C levels. The effects and inter-
actions were demonstrated in univariate and multivariate
models for all subjects, and the protective gene effect
appeared in the stratified high risk group, not in the low risk
group. The significant increases of genotype L than S indi-
cated the protective genetic effects of shorter HO-1 gene
repeats seem work up well in high risk group like low
HDL-C level, and the risk was decreased to the level near
the low risk group like appropriate HDL-C level. All of
patients in our study had no prior CAD or stroke, so our
observation was not confounded by selection bias, such as
survivor for severe disease. It is less considered in previous
studies.
Interestingly, we also described more risk effects of geno-
type L on stroke in those with normal TC or LDL-C levels
than those of genotype S, although the effect was no longer
present in multivariate analysis. Before our study, one study
reported shorter repeats in HO-1 gene exerted a protective
effect on the development of ischemic cerebrovascular
events definitely in patients without hypercholesterolemia
[3]. The finding was similar with that in our study, but they
did not include HDL-C measure. In summary of our find-
ings, the protective effect of HO-1 genotype on ischemic
stroke depended on the presence of lipid conditions, that is,
the levels of HDL-C, it may explain the controversial find-
ings in the literatures.
Similar as the previous CAD studies, we did not find the
significant difference of averaged (GT)n repeats in HO-1
gene promoter between IS and NS patients. Instead, the
lengths of (GT)n repeat seem associated with the ischemic
stroke status only in those individuals with lowered HDL-C
level from our observation and some previous studies. Chen
Table 1: Distribution of CVD risk factor status in stroke patients and their controls
Stroke patients (n = 
183)
Non-stroke patients 
(n = 164)
Variables N (%) N (%) P
Gender Male 114 (62.3) 87 (53.1) 0.0815
Diabetes Yes§ 64 (35.0) 19 (11.6) <0.0001***
Hypertension Yes& 151 (82.5) 90 (54.9) <0.0001***
TC 240 mg/dL+ 26 (14.2) 32 (19.5) 0.1861
Triglyceride 200 mg/dL+ 44 (24.0) 38 (23.2) 0.8480
LDL-C 130 mg/dL+ 52 (28.4) 66 (40.2) 0.0202*
HDL-C <40/50 mg/dL in male/
female
131 (71.6) 68 (41.5) 0.0001***
TC/HDL-C ratio 5+ 66 (36.1) 58 (35.4) 0.8920
Smoker Ever (current/past) 73 (39.9) 47 (28.7) 0.0804
BMI 27 23 (12.6) 40 (24.4) 0.0043**
Plaque score 3 83 (45.3) 43 (26.2) 0.0002***
Genotype L: >26 GT repeats 138 (75.4) 114 (69.5) 0.4262
§ fasting blood glucose 126 mg/dL or on DM medication. &SBP 140 mmHg or DBP 90 mmHg or on anti-hypertension medication. + 
included those patients with related medication. TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; BMI: body mass index. P: the p value from chi-square test between stroke and non-stroke patients. Genotype; the 
length of GT repeats in HO-1 gene promoter. *: p < 0.05; **: p < 0.01; ***: p < 0.001Bai et al. Journal of Biomedical Science 2010, 17:12
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and his coauthors have shown a protection of HO-1 geno-
type in diabetic CAD patients with at least 1 coronary nar-
rowing (>75%) and in restenosis patients after coronary
stenting [24,35]. Another study has shown that the longer
(GT)n repeat in HO-1 gene promoter was related to CAD
risk in diabetic and hypercholesterolemic patients [25].
Interestingly, in the other study, HO-1 gene exerted a pro-
tective effect on ischemic cerebrovascular events in patients
with normal cholesterol level [3]. No effect of HO-1 geno-
type could be observed in total population, they only have
been observed in high risk group or low risk group. It
implies that long (GT)n repeats alone may not be sufficient
to cause diseases. But it may contribute to the development
of the disease when certain conditions of enhanced oxida-
tive stress coexist, including the abnormal composition of
cholesterol levels in patients with normal total cholesterol
levels.
Many studies reported that HO-1 gene involved in the
mechanism against the development of atherosclerosis.
Animal studies reported that products of HO pathway such
Table 2: Distribution of genotype of HO-1 gene promoter by risk factor status in stroke patients and their controls
Stroke patients (n = 183) Non-Stroke patients (n = 164)
Variables Groups S L S L P
All subjects 45 (24.6) 138 (75.4) 50 (30.5) 114 (69.5) 0.4262
Hypertension& Yes 37 (24.5) 114 (35.5) 26 (28.9) 64 (71.1) 0.4535
No 8 (25.0) 24 (75.0) 24 (32.4) 50 (67.6) 0.4441
Diabetes * Yes 10 (15.6) 54 (84.4) 4 (21.1) 15 (79.0) 0.8531
None 35 (29.4) 84 (70.6) 46 (31.7) 99 (68.3) 0.8824
TC 240 mg/dL+ 9 (34.6) 17 (65.4) 6 (18.8) 26 (81.3) 0.2310
Otherwise 36 (22.9) 121 (77.1) 44 (33.3) 88 (66.7) 0.0490 *
Triglyceride 200 mg/dL+ 11 (25.0) 33 (75.0) 13 (34.2) 25 (65.8) 0.4664
Otherwise 34 (24.5) 105 (75.5) 37 (29.4) 89 (70.6) 0.3680
LDL-C 130 mg/dL+ 15 (28.9) 37 (71.2) 14 (21.2) 52 (78.8) 0.3389
Otherwise 30 (22.9) 101 (77.1) 36 (36.7) 62 (63.3) 0.0270 *
HDL-C <40/50 mg/dL 
in male/
female
31 (23.7) 100 (76.3) 29 (42.7) 39 (57.4) 0.0056 **
Otherwise 14 (26.9) 38 (73.1) 21 (21.9) 75 (78.1) 0.4902
TC/HDL-C 
ratio
5+ 14 (21.2) 52 (78.8) 21 (36.2) 37 (63.8) 0.0747
Otherwise 31 (26.5) 86 (73.5) 29 (27.4) 77 (72.6) 0.8758
smoker Current + past 17 (23.3) 56 (76.7) 12 (25.5) 35 (74.5) 0.8288
Otherwise 28 (25.5) 82 (74.6) 38 (32.5) 79 (67.5) 0.3060
BMI 27 6 (26.1) 17 (73.9) 11 (27.5) 29 (72.5) 0.9032
otherwise 38 (24.4) 121 (75.6) 39 (31.4) 85 (68.6) 0.1851
Plaque score 3 19 (22.8) 64 (77.1) 10 (23.3) 33 (76.7) 0.9633
<3 26 (26.0) 74 (74.0) 40 (33.1) 81 (66.9) 0.3018
N(%). * fasting blood glucose 126 mg/dL or on DM medication. &SBP 140 mmHg or DBP 90 mmHg or on anti-hypertension medication. + 
included those patients with related medication. TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol; BMI: body mass index. P: 
the p value from chi-square test comparing genotype S and genotype L between stroke and non-stroke patients in each CVD characteristic 
subgroup. S and L genotypes: averaged (GT)n repeats 26 and >26, respectively. *: p < 0.05; **: p < 0.01; ***: p < 0.001Bai et al. Journal of Biomedical Science 2010, 17:12
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as bilirubin act as a significant protective factor for athero-
sclerosis[27]. The modulation of HO-1 gene expression in
LDL-C receptor-deficient mice influence the progression of
atherosclerosis [17], and mice treated with the HO-1
inducer exhibited reduced atherosclerotic lesion formation.
Vascular proliferation was inhibited by transferring HO-1
gene[18]. These observations support that HO-1 functions
as an intrinsic protective factor against atherosclerotic
lesion formation and may be an anti-atherogenic role in
vascular wall [15].
Chen et al conducted a transient transfection experiment
in rat aortic smooth muscle cells to show that longer (GT)n
repeats in HO-1 promoter decreased luciferase promoter
activity, indicating decrease in gene transcription in vascu-
lar cells[24]. They also found that genotype L/L carriers are
associated with higher extent of sever lipid peroxidation,
supporting the genetic influence of HO-1 on oxidative
stress. Lipid abnormalities like hypercholesterolemia corre-
late with enhanced oxidative stress. HDL-C acts as an anti-
oxidant through its capability of inhibiting LDL-C oxida-
tion, preventing the formation of lipid hydroperoxides
[36,37]. Excessive oxidative stress was considered as a
potential cause of the vascular disease and other complica-
tions in hyperglycemic patients [24,38]. S genotype in the
HO-1 gene promoter may increase the induction of HO-1
by reactive oxygen species in patients with low HDL-C
concentrations. The insufficient effect of anti-oxidative
stress due to lower HDL-C levels may be reversed by S
genotype in HO-1 gene promoter, thereby reducing the risk
of cerebral ischemia.
In this study, the allelic frequency distribution of the
lengths of (GT)n repeats in the HO-1 promoter in recruited
subjects (range from 15 to 39) was similar with that in the
previous reports[23-25,34,35]. The previous studies defined
L and S alleles first and constructed genotypes SS, SL, and
LL to examine the disease risk. We demonstrated the results
assuming co-dominant (additive) model and using averaged
length of two alleles to define genotype L and S, since the
latter is more powerful and fits well the characteristics of
complex model. We also obtained consistent results using
the traditional (former) classification method: the age, sex
& plaque score-adjusted OR of 2.26 (p = 0.0263) and multi-
variate OR of 1.82 (p = 0.0691) in those with lower HDL-C
Table 3: OR on stroke risk of genotype L compared to genotype S in 3 subgroup analyses
Model I Model II
OR (95%CI) P OR (95%CI) P
HDL-C <40/50 mg/
dL in male/
female
2.07 (1.07-4.01) 0.0303 2.02 (1.01-4.02) 0.0465
TC < 240 mg/
dL
1.62 (0.93-2.83) 0.0918 1.63 (0.88-2.39) 0.1182
LDL-C < 130 mg/
dL
1.91 (1.01-3.61) 0.0480 1.63 (0.85-3.13) 0.1435
Odds Ratio (95% confidence interval). TC: total cholesterol. HDL-C: high-density lipoprotein cholesterol. P: the p value from logistic regression 
comparing the genotype L versus genotype S (reference) on stroke risk in each CVD characteristic subgroup. S and L genotypes: averaged 
(GT)n repeats 26 and >26, respectively. Model I: adjusted for age, sex and plaque score; Model II: adjusted for age, sex, hypertension, 
diabetes, ever-smoking, body mass index 27, and plaque score, as well as hyperlipidemia or hypo-HDL-Cholesterolemia depends.
Figure 2 Age- and sex- adjusted odds ratio on stroke risk by HO-
1 genotypes by HDL-C level. Low HDL-C status is HDL-C level less 
than 40 mg/dL in men or 50 mg/dL in women. P-values in parenthesis 
were obtained for each subgroup comparing with the reference group 
(low risk and genotype S), and those p values of 0.05 were not 
showed. Bold p value near curved arrow was obtained for comparing 
risk of genotype L with S in the high risk factor profile group. NS: p 
0.05. *: p < 0.05. **: p < 0.01. ***: p < 0.001
high HDL-C
low HDL-C
Genotype S (Љ26)
Genotype L (Ї26)
0.63
3.2
1
1.44
0
0.5
1
1.5
2
2.5
3
3.5 OR (p=0.009)
(NS) (NS)
P=0.0071** Bai et al. Journal of Biomedical Science 2010, 17:12
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level while those carriers with homozygous S allele (26
GT repeats) as genotype SS compared with otherwise. The
borderline significant findings on HO-1 genotype and cere-
bral ischemia were found in those with low HDL-C level or
in those with high TC/HDL-C ratio. Therefore, the role of
HDL-C associated with developing ischemic stroke exists
identically but underestimated. Such finding focused the
additive effect implied the equal importance in double
helix, then decreasing number of GT repeats act additively
with the increasing protective effects, as some previous
reports described[39,40].
The limitations of this study should be mentioned. Our
study is a case control study. The controls were recruited
from outpatients of the same hospital who seemed to have
higher levels of several CVD risk factors than general pop-
ulation. On the other hand, although we only included the
first case without the history of CAD or stroke to reduce the
selection bias, however, we still not avoid the loss in the
stroke patients died before admission. Fortunately, the num-
ber is few. Taken together, the effect of HO-1 genotype on
ischemic stroke may have been underestimated.
Conclusions
We have demonstrated that the long lengths of (GT)n
repeats in HO-1 gene promoter are associated with the high
risk status on cerebral infarction in subjects with low HDL-
C status. The protection form shorter HO-1 gene promoter
on stroke may be more critical in patients with lower HDL-
C levels than in those with higher HDL-C levels. The find-
ings suggest that genetic characteristics of the HO-1 gene
may interact with the oxidative stress conditions to contrib-
ute to the development of ischemic stroke. These findings
should be confirmed further in population-based studies.
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